Financial Summary
January 1, 2019 - December 31, 2019
Fiscal Year
January 1, 2019 - December 31, 2019
Fiscal Year
-
Consolidated Financial Summary Fiscal 2019
（452KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019
（765KB）
-
Results Presentation Fiscal 2019
（1,045KB）
-
Summary of late-stage clinical trials
（187KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 (text)
（1,499KB）
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2019 Interim
（251KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019 Interim
（490KB）
-
Results Presentation Fiscal 2019 Interim
（740KB）
-
Summary of late-stage clinical trials
（227KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 Interim (text)
（1,035KB）
First Quarter
IR Events
Updates on Nourianz marketing strategy in the U.S. and KW-6356 development
November 19, 2019
On-demand replay (audio) will be available from Nov. 19, 2019 to Nov. 18, 2020.
Update on KHK4083: A phase 1 study in subjects with atopic dermatitis
December 3, 2018
On-demand replay (audio) will be available from Dec. 6, 2018 to Dec. 5, 2019.
Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU
October 27, 2017
IR News
-
February 20, 2020
Notice Regarding Introduction of Restricted Share-Based Remuneration Plan
（87KB）
-
February 05, 2020
Notice Regarding Partial Amendments to the Articles of Incorporation
（116KB）
-
February 05, 2020
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2019
（765KB）
-
February 05, 2020
Consolidated Financial Summary (IFRS) Fiscal 2019
（453KB）
-
October 29, 2019
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2019 Third Quarter
（777KB）
